Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.490
-0.070 (-4.49%)
Sep 12, 2025, 4:00 PM EDT - Market closed
Zentalis Pharmaceuticals Employees
Zentalis Pharmaceuticals had 166 employees as of December 31, 2024. The number of employees decreased by 2 or -1.19% compared to the previous year.
Employees
166
Change (1Y)
-2
Growth (1Y)
-1.19%
Revenue / Employee
$161,837
Profits / Employee
-$980,620
Market Cap
107.48M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 166 | -2 | -1.19% |
Dec 31, 2023 | 168 | 12 | 7.69% |
Dec 31, 2022 | 156 | -21 | -11.86% |
Dec 31, 2021 | 177 | 53 | 42.74% |
Dec 31, 2020 | 124 | 62 | 100.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ZNTL News
- 4 days ago - Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 5 weeks ago - Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress - GlobeNewsWire
- 2 months ago - Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress - GlobeNewsWire
- 4 months ago - Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC - GlobeNewsWire